In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing regimen. More contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be specified as "add-on" therapy. In Segment C, https://holdenhvhsd.estate-blog.com/31401252/helping-the-others-realize-the-advantages-of-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc